Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vicus Therapeutics
Morristown, New Jersey, United Statesvicustherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vicus Therapeutics was a privately-held, clinical-stage biopharmaceutical company focused on developing novel combination therapies for supportive care in oncology. Its lead program, VT‑122—a fixed-dose oral combination of propranolol and etodolac—reached Phase II trials for the treatment of cancer cachexia but was discontinued by September 2021. The company leveraged a proprietary systems biology-based drug reprofiling platform to design synergistic two-drug regimens from existing marketed drugs. Other pipeline programs targeted oral mucositis and cancer fatigue at preclinical stages. All known development programs have been discontinued as of the latest available information.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesdrug combinations
- Industry
- Biotech
Beyond the preview
Go deeper on Vicus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vicus Therapeutics.